Large drugmakers moved this month to deploy AI as an enterprise discovery engine, signing multi-target platform agreements with AI startups. Eli Lilly, GSK and Pfizer each struck deals to integrate AI platforms from firms including Chai Discovery, Noetik and Boltz, shifting collaborations from single-program deals to broad technology partnerships. Chai’s Chai‑2 model—reported in a bioRxiv preprint to raise success rates for de novo antibody design—illustrates the capability vendors promise. "Platform" AI in this context refers to scalable, model-driven discovery and optimization tools that can be trained on proprietary data and applied across multiple programs.